☆ 4.6 Article

Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Efficacy of Tocilizumab in Management of COVID-19 Patients Admitted to Intensive Care Units: A Multicenter Retrospective Cohort Study

Hoda Younes Ibrahem et al.

Summary: This study aimed to determine the efficacy of Tocilizumab on patients' survival and the length of stay in hospitalized COVID-19 patients admitted to the intensive care unit. The results showed no statistically significant difference between patients treated with TCZ and the control group in terms of the primary outcome (discharged alive or death) and the secondary outcome (length of hospital stay).

MEDICINA-LITHUANIA (2023)

Add to Collection

Letter Hematology

Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors

Wei Yee Chan et al.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Letter Hematology

Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study

Nicola Sgherza et al.

HAEMATOLOGICA (2022)

Add to Collection

Editorial Material Oncology

Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination

Evangelos Terpos et al.

JAMA ONCOLOGY (2022)

Add to Collection

Letter Hematology

SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance

Nicola Sgherza et al.

HEMASPHERE (2022)

Add to Collection

Article Oncology

Impact of COVID-19 in patients with multiple myeloma based on a global data network

J. Martinez-Lopez et al.

Summary: By analyzing global medical data, it was found that the COVID-19 pandemic has had a more severe impact on multiple myeloma (MM) patients, including reducing the number of new diagnoses, decreasing survival rates, increasing infection risks, and raising mortality rates. Therefore, it is necessary to strengthen preventive measures globally to protect vulnerable patients at risk of infection and death.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Article Hematology

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience

Marta Krejci et al.

Summary: Infections are the primary cause of morbidity and mortality in multiple myeloma patients, and a study found that 14% of MM outpatients treated with novel drugs were diagnosed with COVID-19, with a majority having a moderate to serious course of the disease. Among these patients, 56% required hospitalization and 18% died. Factors associated with COVID-19 hospitalization and death included disease responsiveness, ECOG performance status, and comorbidities.

ANNALS OF HEMATOLOGY (2021)

Add to Collection

Letter Oncology

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Oliver Van Oekelen et al.

CANCER CELL (2021)

Add to Collection

Article Oncology

Response to mRNA vaccination for COVID-19 among patients with multiple myeloma

Samuel D. Stampfer et al.

Summary: Patients with multiple myeloma have impaired responses to mRNA vaccination against COVID-19, with those with active disease showing poorer responses. Factors such as age, renal function, immunoglobulin levels, among others, can predict vaccine responsiveness in these patients. Additionally, patients vaccinated with mRNA-1273 had higher anti-spike antibody levels compared to those vaccinated with BNT162b2.

LEUKEMIA (2021)

Add to Collection

Article Oncology

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

Evangelos Terpos et al.

Summary: Recent data shows suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Specifically, patients with multiple myeloma (MM) exhibit lower production of neutralizing antibodies (NAbs) after vaccination compared to healthy controls, especially when undergoing treatment with anti-CD38 or belamaf. Timely vaccination, possibly during treatment-free periods, is emphasized for this group of patients.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Environmental Sciences

Using Machine Learning Algorithms to Develop a Clinical Decision-Making Tool for COVID-19 Inpatients

Abhinav Vepa et al.

Summary: The study aimed to develop a reliable, multivariable predictive model for COVID-19 in-patient outcomes using anonymized data, feature selection with random forests, and Bayesian networks. The proposed probabilistic models successfully predicted the probability of outcomes and demonstrated the potential as useful tools for risk stratification and clinical decision-making. Further research is needed to externally validate and confirm the utility of these models.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)

Add to Collection

Letter Hematology

Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy

Gordon Cook et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Article Oncology

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

Bo Wang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Hematology

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Ajai Chari et al.

BLOOD (2020)

Add to Collection

Article Multidisciplinary Sciences

Predictors of intensive care unit admission in patients with hematologic malignancy

Abi Vijenthira et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Oncology

Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

Oksana Zavidij et al.

NATURE CANCER (2020)

Add to Collection

Article Immunology

Comparative Study of Immune Status to Infectious Agents in Elderly Patients with Multiple Myeloma, Waldenstrom's Macroglobulinemia, and Monoclonal Gammopathy of Undetermined Significance

Johanna Karlsson et al.

CLINICAL AND VACCINE IMMUNOLOGY (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.